Evidence map›Paper›PMID 33717420›Full record

ArticleNano research2021

Is Tumor Cell Specificity Distinct from Tumor Selectivity In Vivo?: A Quantitative NIR Molecular Imaging Analysis of Nanoliposome Targeting.

Girgis Obaid, Kimberley Samkoe, Kenneth Tichauer, Shazia Bano, Yeonjae Park, Zachary Silber, Sassan Hodge, Susan Callaghan, Mina Guirguis, Srivalleesha Mallidi and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Dynamic Tracking ofMolecular pharmaceutics · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Girgis ObaidWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, U.S.
Kimberley SamkoeThayer School of Engineering, Dartmouth College, Hanover, New Hampshire 037551, U.S.
Kenneth TichauerArmour College of Engineering, Illinois Institute of Technology, Chicago, Illinois 60616, U.S.
Shazia BanoWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, U.S.
Yeonjae ParkThayer School of Engineering, Dartmouth College, Hanover, New Hampshire 037551, U.S.
Zachary SilberWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, U.S.
Sassan HodgeThayer School of Engineering, Dartmouth College, Hanover, New Hampshire 037551, U.S.
Susan CallaghanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, U.S.
Mina GuirguisDepartment of Bioengineering, University of Texas at Dallas, Richardson, Texas 75080, U.S.
Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, U.S.
Brian PogueThayer School of Engineering, Dartmouth College, Hanover, New Hampshire 037551, U.S.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, U.S.
Dartmouth College · USHarvard University · USMassachusetts General Hospital · USIllinois Institute of Technology · USThe University of Texas at Dallas · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tayyaba Hasan · 2001 to 2026
$27.9M
Paired-agent imaging for resection during surgery (PAIRS) for head & neck cancersR37CA212187 · NCI · DARTMOUTH-HITCHCOCK CLINIC · PI SAMKOE, KIMBERLEY · 2018 to 2024
$2.7M
Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsR00CA215301 · NCI · UNIVERSITY OF TEXAS DALLAS · PI OBAID, GIRGIS · 2020 to 2022
$721k
Optical imaging guided resection and photodynamic therapy of glioma with targeted photoactivable agentsR21CA220143 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2017 to 2019
$390k
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsK99CA215301 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI OBAID, GIRGIS · 2018 to 2019
$358k
NCI NIH HHS K99 CA215301NCI NIH HHS P01 CA084203NCI NIH HHS R00 CA215301NCI NIH HHS R01 CA156177NCI NIH HHS R01 CA160998NCI NIH HHS R21 CA220143NCI NIH HHS R37 CA212187
6 · The paper itself

Abstract

The significance and ability for receptor targeted nanoliposomes (tNLs) to bind to their molecular targets in solid tumors

Indexed as

CancerMolecular RecognitionNanoparticlesReceptorsSpecificity

Identifiers

PMID33717420
PMCPMC7951968
OpenAlexW3107895304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.